surmount-1 trial tirzepatide obesity without diabetes on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial tirzepatide obesity without – SURMOUNT-1: Tirzepatide Drastically Reduces Weight

10.1006/pmpp.2003.0445 76 LisenbeeC

This review article will discuss the pharmacology of orally administered semaglutide with a focus on role of SNAC in enhancing the absorption of semaglutide, in addition to efficacy and safety from the PIONEER trials to determine its potential therapeutic role

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 251,40 per year only 20,95 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

For patients taking levothyroxine, additional considerations apply